DDC News
Archive
April 14, 2022: A paper titled "Colchicine-binding site agent CH-2-77 as a potent tubulin inhibitor suppressing triple-negative breast cancer鈥� is accepted by Molecular Cancer Therapeutics. It is a collaboration paper between DDC members Li, Miller, and Meibohm, along with other co-authors.
April 11, 2022: as announced by Veru, Inc., who licensed and is developing Sabizabulin for cancer and COVID-19 indication. Sabizabulin (other names as VERU-111, ABI-231) was first made in the Li lab in collaboration with the Miller lab in 2011.
April 1, 2022: A collaboration project led by the Yang lab and an investigator at Cleveland Clinic has led to a new 2-year R21 CA270590 grant from NIH/NCI, for a total of $414,343. The goal of the project is to develop inhibitors听targeting a mutant splicing factor U2AF1 in myeloid malignancies. .
Jan 31, 2022: The Jiang lab and Li lab published a collaborative paper, titled 鈥溾�� in Epilepsia.
Jan 10, 2022: The Yang lab and Li lab published a collaborative paper, titled 鈥溾�� in ACS Medicinal Chemistry Letters.
December 12, 2021:听the DDC welcome Dr. Santosh Kumar, Professor in Pharmaceutical Sciences and Assistant Dean for Scholarly Integration and Collaboration, and an expert in HIV and exosomes research areas, to join DDC.听
December 8, 2021: Technology described in DDC member Dr. Jiang鈥檚 recent patent (US10758516) 鈥淢ethods and compositions for the treatment of gliomas鈥� has been exclusively licensed to Nuvision Benefits, a Vancouver-based biopharmaceutical company.
December 3, 2021: In the 2021 Annual Postdoc Research Showcase, 17 postdocs from the UTHSC campus presented their research and competed for the four Virtual Presentation awards and the three Travel awards. Two postdocs from members of the DDC did fantastic jobs. For the Presentation award, Dr. Lexiao Li from the Jiang lab received the 1st place award, and Dr. Vijay Kumar Boda from the Li lab received the 4th place award. Both Dr. Vijay Boda and Dr. Lexiao Li also received the travel awards. Congratulations to Lexiao and Vijay for this outstanding performance.
November 25, 2021: Research Topic 鈥溾�� for Frontiers in Cell and Developmental Biology (2020 IF: 6.684) is now open for submissions. DDC member Dr. Jiang is the Associate Editor for this topic.
November 22, 2021: A collaboration project by the Jiang lab and the Li lab led to a new 3-year R61/R33 NS124923 grant from NIH/NINDS, for a total of $1.15 million. The goal of the project is to develop selective TRPC3 inhibitors as potential new targeted therapy for epilepsy.
November 15, 2021:
July 29, 2021: Paper 鈥溾�� authored by Madison Sluter et al. in Jiang lab was accepted for publication by the Journal of Medicinal Chemistry.
June 16, 2021: An in Jiang lab, who won the 2021 Epilepsia Open Prize for Basic Science Research by the International League Against Epilepsy (ILAE).
听